Combined anti-PD1 immunotherapy for patient with advanced pancreatic cancer: A case report
Pancreatic cancer (PC) is a highly lethal malignancy with a dismal 5-year survival rate. The current treatment modalities for the treatment-associated toxicity of immunotherapy-based approaches are limited. Immunotherapy for PC was needed to be further investigated. This report illustrates the combined use of anti PD-1 immunotherapy with other therapeutic strategies for cancer pain. In this case, a patient with PC was treated with surgical resection, chemotherapy, molecular targeted medicine, and anti-PD1 immunotherapy. The survival period of the patient was more than 6 years since diagnosis. Finally, we will present our perspective on the future development of immunotherapy for PC. In a word, this case report sheds lights on information that would be helpful for more rigorous exploration of PC treatments.
Raimondi S, Maisonneuve P, Lowenfels AB, 2009, Epidemiology of pancreatic cancer: An overview. Nat Rev Gastroenterol Hepatol, 6(12): 699–708. https://doi.org/10.1038/nrgastro.2009.177
Klein AP, Brune KA, Petersen GM, et al., 2004, Prospective risk of PC in familial PC kindreds. Cancer Res, 64(7): 2634–2638.
Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al., 2009, Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet, 41(9): 986–990.
Wolpin BM, Chan AT, Hartge P, et al., 2009, ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst, 101(6): 424–431.
Li D, Yeung SC, Hassan MM, et al., 2009, Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology, 137(2): 482–488. https://doi.org/10.1053/j.gastro.2009.04.013
Blackford A, Parmigiani G, Kensler TW, et al., 2009, Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res, 69(8): 3681–3688.
Moore MJ, Goldstein D, Hamm J, et al., 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol, 25(15): 1960–1966. https://doi.org/10.1200/jco.2005.23.16_suppl.1
Sun J, Wan Z, Chen Y, et al., 2020, Triple drugs co-delivered by a small gemcitabine-based carrier for PC immunochemotherapy. Acta Biomater, 106: 289–300. https://doi.org/10.1016/j.actbio.2020.01.039
Wu D, Lv J, Zhao R, et al., 2020, PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomark Res, 8: 3–16. https://doi.org/10.1186/s40364-020-0183-x
Gautam SK, Kumar S, Dam V, et al., 2020, MUCIN-4 (MUC4) is a novel tumor antigen in PC immunotherapy. Semin Immunol, 14: 101391–101399. https://doi.org/10.1016/j.smim.2020.101391
Okusaka T, Furuse J, 2020, Recent advances in chemotherapy for pancreatic cancer: Evidence from Japan and recommendations in guidelines. J Gastroenterol, 55(4): 369–382. https://doi.org/10.1007/s00535-020-01666-y
Schizas D, Charalampakis N, Kole C, et al., 2020, Immunotherapy for pancreatic cancer: A 2020 update. Cancer Treat Rev, 86: 102016. https://doi.org/10.1016/j.ctrv.2020.102016
Tivadar ST, McIntosh RS, Chua JX, et al., 2020, Monoclonal antibody targeting sialyl-di-Lewisa-containing internalizing and noninternalizing glycoproteins with cancer immunotherapy development potential. Mol Cancer Ther, 19(3): 790–801. https://doi.org/10.1158/1535-7163.mct-19-0221